These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31173259)

  • 1. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
    Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
    Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
    Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
    J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
    Robaina MC; Mazzoccoli L; Arruda VO; Reis FR; Apa AG; de Rezende LM; Klumb CE
    Exp Mol Pathol; 2015 Apr; 98(2):200-7. PubMed ID: 25746661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 5' regulatory sequences of active miR-146a promoters are hypomethylated and associated with euchromatic histone modification marks in B lymphoid cells.
    Szenthe K; Koroknai A; Banati F; Bathori Z; Lozsa R; Burgyan J; Wolf H; Salamon D; Nagy K; Niller HH; Minarovits J
    Biochem Biophys Res Commun; 2013 Apr; 433(4):489-95. PubMed ID: 23528241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
    Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.
    Seitz V; Butzhammer P; Hirsch B; Hecht J; Gütgemann I; Ehlers A; Lenze D; Oker E; Sommerfeld A; von der Wall E; König C; Zinser C; Spang R; Hummel M
    PLoS One; 2011; 6(11):e26837. PubMed ID: 22102868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
    Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
    PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral driven epigenetic events alter the expression of cancer-related genes in Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines.
    Hernandez-Vargas H; Gruffat H; Cros MP; Diederichs A; Sirand C; Vargas-Ayala RC; Jay A; Durand G; Le Calvez-Kelm F; Herceg Z; Manet E; Wild CP; Tommasino M; Accardi R
    Sci Rep; 2017 Jul; 7(1):5852. PubMed ID: 28724958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines.
    Jansson A; Masucci M; Rymo L
    J Virol; 1992 Jan; 66(1):62-9. PubMed ID: 1370095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-promoter regions.
    Minarovits J; Hu LF; Minarovits-Kormuta S; Klein G; Ernberg I
    Virology; 1994 May; 200(2):661-7. PubMed ID: 8178450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
    Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
    Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
    J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
    Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
    BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
    Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
    Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
    Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
    J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.
    Piccaluga PP; Navari M; De Falco G; Ambrosio MR; Lazzi S; Fuligni F; Bellan C; Rossi M; Sapienza MR; Laginestra MA; Etebari M; Rogena EA; Tumwine L; Tripodo C; Gibellini D; Consiglio J; Croce CM; Pileri SA; Leoncini L
    Oncotarget; 2016 Jan; 7(1):224-40. PubMed ID: 26325594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
    Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
    Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.